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Compounds that target estrogen receptors (ERs) show promise as a potential treatment for endometriosis in a study of both a mouse model of the disease and in human cells.
Women with endometriosis suffer from painful invasive lesions, resulting from attachment of endometrial tissue to sites outside of the uterus. The hormone estrogen drives the disease (the lesions have aberrant ER expression), but the condition is also thought to involve an inflammatory response associated with the lesions. Aromatase inhibitors or other drugs that choke off the supply of estrogen are currently the standard for care. But these drugs are imperfect-for instance, they can result in side effects such as reduced bone density and changes to fertility. Treatment is often a struggle for people with the condition, which is 10 to 14 percent of reproductive-age women.
To attempt to circumvent such problems, Yuechao Zhao et al. tested two newly developed ER ligands [1] . These ligands block multiple activities of estrogen but have been optimized to be particularly effective at blocking the hormone's proinflammatory effects (Fig. 1) . One of the ligands, chloroindazole (CLI), has activity against ERb; and the other, oxabicycloheptene sulfonate (OBHS), preferentially targets the other major receptor, ERa.
The researchers tested the drugs in a mouse model of endometriosis and found that each of the drugs, CLI or OBHS, could block new lesions and shrink existing lesions as well as quell inflammation within the lesions and stunt the growth of blood vessels and neurons into the lesions, events that are thought to contribute to pain. Moreover, the drugs seemed to synergize with letrozole, an aromatase inhibitor.
Similarly to the mice, cells derived from human endometriosis lesions responded to CLI or OBHS by slowing growth, increasing apoptosis, and shutting down the production of inflammatory mediators.
The drugs did not appear to affect fertility-at the concentrations effective for treatment, the mice appeared to have normal ovarian function and had the same number of pups as untreated mice without the condition. These findings set the stage for tests in non-human primates.
